Management of anti-D prophylaxis in RhD negative women undergoing early medical abortion – an international practice survey among practitioners

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F25%3A10159384" target="_blank" >RIV/00098892:_____/25:10159384 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/25:73633021

Výsledek na webu

<a href="https://www.tandfonline.com/doi/full/10.1080/13625187.2025.2486690#abstract" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/13625187.2025.2486690#abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/13625187.2025.2486690" target="_blank" >10.1080/13625187.2025.2486690</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Management of anti-D prophylaxis in RhD negative women undergoing early medical abortion – an international practice survey among practitioners

Popis výsledku v původním jazyce

Aim: We evaluated the current practices of abortion providers giving anti-D prophylaxis to RhD negative women undergoing first trimester medical abortion and factors that influenced the decision. We also examined RhD management strategies that could be safely adopted. Methods: A Steering Committee of abortion providers drafted a questionnaire on anti-D prophylaxis practices and perceptions. The 28-question survey, hosted online from December 2022 to December 2023, targeted international abortion providers. Results: Almost 62% of respondents perform medical abortion during the first trimester (up to 12 weeks of amenorrhoea [WA]), while 32.8% provide it during the second trimester (13 to 26 WA). Among providers, 55.8% administer anti-D prophylaxis to all RhD negative women during first trimester medical abortions, 25.5% provide it selectively, and 18.6% do not administer it at all. Providers who do not administer IgG anti-D rely on national guidelines (51.2%), hospital protocols (16.3%), or both (7.0%), citing early gestational age (36.5%) and insufficient evidence (22.9%) as reasons. The primary reason for administering IgG anti-D was preventing risks in future pregnancies (52.7%). Yet, 59.1% expressed interest in changing their anti-D prophylaxis practices during early abortion. Conclusion: This study highlights the huge variations in anti-D prophylaxis practices during first trimester medical abortion. These discrepancies mirror differences in national and international guidelines and underscore the need for robust clinical evidence to determine the gestational age limits for alloimmunization risk and support protocol updates.

Název v anglickém jazyce

Management of anti-D prophylaxis in RhD negative women undergoing early medical abortion – an international practice survey among practitioners

Popis výsledku anglicky

Aim: We evaluated the current practices of abortion providers giving anti-D prophylaxis to RhD negative women undergoing first trimester medical abortion and factors that influenced the decision. We also examined RhD management strategies that could be safely adopted. Methods: A Steering Committee of abortion providers drafted a questionnaire on anti-D prophylaxis practices and perceptions. The 28-question survey, hosted online from December 2022 to December 2023, targeted international abortion providers. Results: Almost 62% of respondents perform medical abortion during the first trimester (up to 12 weeks of amenorrhoea [WA]), while 32.8% provide it during the second trimester (13 to 26 WA). Among providers, 55.8% administer anti-D prophylaxis to all RhD negative women during first trimester medical abortions, 25.5% provide it selectively, and 18.6% do not administer it at all. Providers who do not administer IgG anti-D rely on national guidelines (51.2%), hospital protocols (16.3%), or both (7.0%), citing early gestational age (36.5%) and insufficient evidence (22.9%) as reasons. The primary reason for administering IgG anti-D was preventing risks in future pregnancies (52.7%). Yet, 59.1% expressed interest in changing their anti-D prophylaxis practices during early abortion. Conclusion: This study highlights the huge variations in anti-D prophylaxis practices during first trimester medical abortion. These discrepancies mirror differences in national and international guidelines and underscore the need for robust clinical evidence to determine the gestational age limits for alloimmunization risk and support protocol updates.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The European Journal of Contraception and Reproductive Health Care

ISSN

1362-5187

e-ISSN

1473-0782

Svazek periodika

30

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

205-215

Kód UT WoS článku

001472319200001

EID výsledku v databázi Scopus

2-s2.0-105003250290